Bezlotoxumab Disease Interactions
There are 2 disease interactions with bezlotoxumab.
Bezlotoxumab (applies to bezlotoxumab) CHF
Major Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure
Heart failure was reported more frequently with bezlotoxumab than with placebo in two Phase 3 clinical trials, and occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of bezlotoxumab-treated patients and 4.8% (5/104) of placebo-treated patients had heart failure as an adverse reaction during the 12-week study period, and 19.5% (23/118) versus 12.5% (13/104) died, respectively. The causes of death varied and included cardiac failure, infections, and respiratory failure. Therapy with bezlotoxumab should be reserved for use only when the benefit outweighs the risk in patients with a history of CHF.
References
- (2016) "Product Information. Zinplava (bezlotoxumab)." Merck & Co., Inc
Bezlotoxumab (applies to bezlotoxumab) congestive heart failure
Moderate Potential Hazard, Moderate plausibility.
Bezlotoxumab should be used with caution in patients with a history of congestive heart failure, and it should be reserved for use when the benefits outweigh the risk.
References
- (2016) "Product Information. Zinplava (bezlotoxumab)." Merck & Co., Inc
Bezlotoxumab drug interactions
There are 2 drug interactions with bezlotoxumab.
More about bezlotoxumab
- bezlotoxumab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: immune globulins
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.